GlassScriptPhysician profile
Hani A Zamil
NPI 1346430477
$35,796.05
in general payments reported to CMS, 2019-2025
37 companies · $1,070 in 2025
The $1,070 reported for 2025 was more than what a typical Gastroenterology (Internal Medicine) provider received nationally (typical 2025 total: $636).
See the full distribution for Gastroenterology (Internal Medicine)
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,969 · 2020: $9,569 · 2021: $17K · 2022: $3,363 · 2023: $776 · 2024: $2,214 · 2025: $1,070.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $3,286 · Travel and Lodging: $774.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $3,285.87 |
| Travel and Lodging | $773.80 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Medical Device Business Services, INC. | $22,542.31 | 2019-2022 | |
| Medtronic, INC. | $5,762.15 | 2021-2025 | Endoflip, Manoscan, Barrx |
| Ethicon US, LLC | $1,520.24 | 2019-2021 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $1,019.52 | 2020-2025 | Trulance, Xifaxan, Plenvu |
| Abbvie INC. | $938.73 | 2021-2025 | Linzess, Rinvoq, Viberzi |
| Merck Sharp & Dohme LLC | $512.08 | 2020-2024 | Dificid |
| Qol Medical, LLC | $403.39 | 2019-2023 | Sucraid |
| Janssen Biotech, INC. | $321.90 | 2021-2025 | Tremfya, Stelara |
| Olympus Corporation of The Americas | $314.13 | 2019 | |
| Takeda Pharmaceuticals U.S.A., INC. | $294.00 | 2024-2025 | Entyvio, Gattex |
| Ironwood Pharmaceuticals, INC | $274.79 | 2021-2024 | Linzess |
| Regeneron Healthcare Solutions, INC. | $195.12 | 2024-2025 | Dupixent |
| Genzyme Corporation | $185.25 | 2023-2025 | |
| Covidien LP | $181.47 | 2019-2020 | |
| Nestle Healthcare Nutrition INC. | $180.00 | 2021-2023 |
Show all 36 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Boston Scientific Corporation | $119.05 | 2019 | |
| Evoke Pharma, INC. | $102.93 | 2022-2024 | Gimoti |
| Aimmune Therapeutics, INC. | $99.57 | 2024-2025 | Zenpep, Vowst |
| Celgene Corporation | $97.56 | 2022-2024 | Zeposia |
| Aries Pharmaceuticals, INC. | $90.29 | 2019 | |
| Braintree Laboratories, INC. | $88.08 | 2020-2023 | Suflave, Sutab |
| Vivus LLC | $77.49 | 2024 | Qsymia |
| Ardelyx, INC. | $76.88 | 2024 | Ibsrela |
| Ferring Pharmaceuticals INC. | $61.64 | 2021-2022 | |
| Madrigal Pharmaceuticals | $56.73 | 2024-2025 | Rezdiffra, Resmetirom |
| Lumendi LLC | $51.61 | 2019 | |
| Phathom Pharmaceuticals, INC. | $42.16 | 2024-2025 | Voquezna |
| Olympus America INC. | $28.16 | 2020-2023 | Endoclot Phs |
| Ambu INC. | $27.49 | 2020-2021 | |
| Astrazeneca Pharmaceuticals LP | $22.63 | 2024 | Andexxa |
| Gilead Sciences, INC. | $20.98 | 2023 | |
| Azurity Pharmaceuticals, INC. | $20.58 | 2025 | Suflave |
| Alfasigma USA, INC. | $19.71 | 2020 | |
| Novo Nordisk INC | $19.29 | 2025 | Wegovy |
| Pfizer INC. | $14.67 | 2025 | |
| Alexion Pharmaceuticals, INC. | $13.47 | 2021 |
1 company reported research payments only; those appear in the research section below.
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Hani Zamil listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.